DSpace Repository

Drugs for neglected diseases: a failure of the market and a public health failure?

Show simple item record

dc.contributor Centre Hospitalier Universitaire de Grenoble, Grenoble, France.
dc.creator Trouiller, P
dc.creator Torreele, E
dc.creator Olliaro, P
dc.creator White, N J J
dc.creator Foster, S
dc.creator Wirth, D
dc.creator Pécoul, B
dc.date 2001-11
dc.date.accessioned 2017-01-31T07:11:10Z
dc.date.available 2017-01-31T07:11:10Z
dc.identifier Drugs for neglected diseases: a failure of the market and a public health failure? 2001, 6 (11):945-51 Trop. Med. Int. Health
dc.identifier 1360-2276
dc.identifier 11703850
dc.identifier http://hdl.handle.net/10144/28439
dc.identifier http://fieldresearch.msf.org/msf/handle/10144/28439
dc.identifier Tropical Medicine & International Health
dc.identifier.uri http://dspace.mediu.edu.my:8181/xmlui/handle/10144/28439
dc.description Infectious diseases cause the suffering of hundreds of millions of people, especially in tropical and subtropical areas. Effective, affordable and easy-to-use medicines to fight these diseases are nearly absent. Although science and technology are sufficiently advanced to provide the necessary medicines, very few new drugs are being developed. However, drug discovery is not the major bottleneck. Today's R&D-based pharmaceutical industry is reluctant to invest in the development of drugs to treat the major diseases of the poor, because return on investment cannot be guaranteed. With national and international politics supporting a free market-based world order, financial opportunities rather than global health needs guide the direction of new drug development. Can we accept that the dearth of effective drugs for diseases that mainly affect the poor is simply the sad but inevitable consequence of a global market economy? Or is it a massive public health failure, and a failure to direct economic development for the benefit of society? An urgent reorientation of priorities in drug development and health policy is needed. The pharmaceutical industry must contribute to this effort, but national and international policies need to direct the global economy to address the true health needs of society. This requires political will, a strong commitment to prioritize health considerations over economic interests, and the enforcement of regulations and other mechanisms to stimulate essential drug development. New and creative strategies involving both the public and the private sector are needed to ensure that affordable medicines for today's neglected diseases are developed. Priority action areas include advocating an essential medicines R&D agenda, capacity-building in and technology transfer to developing countries, elaborating an adapted legal and regulatory framework, prioritizing funding for essential drug development and securing availability, accessibility, distribution and rational use of these drugs.
dc.language en
dc.publisher Wiley-Blackwell
dc.rights Archived on this site with the kind permission of Wiley-Blackwell, [url]http://www.blackwell-synergy.com/loi/tmi[/url]
dc.title Drugs for neglected diseases: a failure of the market and a public health failure?

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account